Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceftobiprole - Basilea Pharmaceutica

Next Previous
Drug Profile

Ceftobiprole - Basilea Pharmaceutica

Alternative Names: BAL 9141-000; BAL9141; Ro-63-9141

Latest Information Update: 11 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Basilea Pharmaceutica; Roche
  • Class Anti-infectives; Antibacterials; Cephalosporins; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell wall inhibitors; Peptidyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Methicillin-resistant Staphylococcus aureus infections
  • Discontinued Nosocomial infections

Most Recent Events

  • 25 Feb 2025 Basilea Pharmaceutica completes a phase I trial (In volunteers) in Netherlands (IV) (NCT06808646)
  • 17 Jan 2025 Phase-I clinical trials in Methicillin resistant Staphylococcus aureus infections (In volunteers) in Netherlands (IV) (NCT06808646)
  • 27 Apr 2024 Antimicrobial data from a phase-III ERADICATE trial in Methicillin-resistant Staphylococcus aureus infection presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious (ECCMID 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top